XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (62,086) $ (164,808)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 937 1,232
Inventory obsolescence 1,361 236
Stock-based compensation expense 44,074 39,127
Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs 53,571 66,286
Amortization of premium/discount on investments (8,713) (6,814)
Loss on extinguishment of debt 0 29,019
Changes in operating assets and liabilities:    
Receivables (15,402) (3,125)
Inventory (2,001) (2,357)
Prepaid expenses and other assets 1,385 (7,530)
Accounts payable and accrued expenses (59,933) (36,678)
Deferred revenue 0 (811)
Net cash used in operating activities (46,807) (86,223)
Cash flows from investing activities:    
Acquisitions of property and equipment (449) (1,614)
Purchase of investments (227,235) (357,419)
Maturities of investments 262,480 256,008
Net cash provided by (used in) investing activities 34,796 (103,025)
Cash flows from financing activities:    
Net proceeds from common stock issued under stock-based compensation plans 4,030 8,301
Common stock issued to directors in lieu of cash retainer 29 217
Withholding taxes paid on stock-based awards (4,451) 0
Net proceeds from Pharmakon Tranche A term loan 0 300,000
Repayment of Athyrium secured term loans principal 0 (240,452)
Prepayment and repayment fees on Athyrium secured term loans 0 (21,261)
Payment of debt issuance costs on Pharmakon Tranche A term loan 0 (11,147)
Principal payments on finance lease liabilities (1,348) 0
Net cash (used in) provided by financing activities (1,740) 35,658
Effect of exchange rate on cash, cash equivalents, and restricted cash 368 (160)
Decrease in cash, cash equivalents and restricted cash (13,383) (153,750)
Cash, cash equivalents and restricted cash at beginning of period 112,447 306,239
Cash, cash equivalents and restricted cash at end of period 99,064 152,489
Supplemental Cash Flow Information [Abstract]    
Cash paid for interest 20,242 17,151
Cash paid for taxes 1,225 1,444
Taxes withheld on stock-based awards included in accrued expenses $ 245 $ 2,107